KPV
Immune & Anti-InflammatoryAlso known as: Lys-Pro-Val, Alpha-MSH Fragment, Alpha-MSH(11-13), KPV Tripeptide
Mechanism
KPV is a tiny three-amino-acid peptide fragment derived from the anti-inflammatory hormone alpha-MSH. Despite its small size, it has potent anti-inflammatory effects, particularly in the gut, where it helps calm inflammatory bowel conditions by reducing the activity of inflammatory signaling pathways. It is commonly used for gut inflammation, skin conditions, and general inflammatory issues, and can be taken orally or used topically.
Technical detail
KPV is a C-terminal tripeptide (Lys-Pro-Val) fragment of alpha-melanocyte-stimulating hormone, positions 11-13. It exerts anti-inflammatory activity primarily through inhibition of the NF-kB signaling pathway by preventing nuclear translocation of the p65 subunit and IkBa phosphorylation, independent of classical melanocortin receptor binding. It has demonstrated efficacy in reducing pro-inflammatory cytokine production (TNF-a, IL-6, IL-1B) in colonocyte and macrophage models, and oral administration in colitis models showed mucosal healing comparable to conventional anti-inflammatory agents.
Effects
**Immune/Inflammatory System (Tier 2 — Translational Research):** KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the anti-inflammatory activity of the parent molecule WITHOUT melanocortin receptor binding (no skin darkening, no appetite effects). KPV exerts anti-inflammatory effects through: (1) inhibition of NF-kB nuclear translocation — blocks the master switch of inflammatory gene transcription; (2) reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8); (3) inhibition of nitric oxide synthase (iNOS) and COX-2 expression; (4) suppression of NLRP3 inflammasome activation. **Gastrointestinal System (Tier 2 — Key Application):** KPV has particular affinity for inflamed gut tissue. Studies in experimental colitis models show oral KPV reduces mucosal inflammation, decreases inflammatory cell infiltration, and promotes epithelial barrier restoration. The PepT1 transporter (expressed on intestinal epithelial cells) actively transports KPV into colonocytes, providing targeted delivery to inflamed gut tissue. This makes oral KPV uniquely suited for GI inflammatory conditions. **Gut Barrier / Microbiome (Tier 2-3):** KPV reduces intestinal permeability by suppressing inflammatory disruption of tight junction proteins (occludin, ZO-1, claudins). By reducing mucosal inflammation, KPV creates an environment favorable for microbiome rebalancing. Does NOT directly kill bacteria (unlike LL-37) — it works by calming the inflammatory milieu. **Skin/Dermatological (Tier 2):** Anti-inflammatory effects extend to skin — KPV reduces UV-induced inflammation, allergic skin reactions, and inflammatory dermatoses in animal models. Being investigated for atopic dermatitis, psoriasis, and wound healing (reduces inflammatory phase, promotes resolution). **CNS/Neuroinflammation (Tier 3):** KPV crosses the blood-brain barrier. In animal models of neuroinflammation, it reduces microglial activation, brain cytokine levels, and neuronal damage. Potential application in neuroinflammatory conditions (traumatic brain injury, neurodegenerative disease).
Practitioner Guide
**Gut Dysbiosis / Leaky Gut / IBD Protocol:** - Oral KPV: 200-500mcg daily, taken on empty stomach (for GI-targeted effect) - The PepT1 transporter actively imports KPV into intestinal epithelial cells — oral route provides direct gut targeting - Duration: 4-12 weeks as part of a comprehensive gut restoration protocol - Often combined with: BPC-157 (tissue repair), LL-37 (antimicrobial/biofilm), larazotide (tight junction support) - Sequence: some practitioners start with LL-37 (2-4 weeks to address infection/biofilm) then add KPV (anti-inflammatory) + BPC-157 (repair) **Mold Illness / CIRS Protocol:** - KPV addresses the chronic inflammatory cascade in CIRS (elevated TGF-beta, C4a, MMP-9) - Dose: 200-500mcg oral daily OR 200-400mcg SC daily - SC route for systemic anti-inflammatory effect; oral route for gut-specific inflammation - Often combined with VIP (nasal — addresses different inflammatory pathways) and LL-37 (biofilm disruption for MARCoNS) - In Shoemaker-style CIRS treatment: KPV can be used alongside binders (cholestyramine/welchol) to reduce inflammatory burden - Duration: 8-12 weeks minimum; some patients benefit from longer courses **Lyme Disease / Chronic Infection Protocol:** - KPV complements LL-37 in Lyme protocols: LL-37 handles antimicrobial/biofilm disruption, KPV manages the inflammatory response - Dose: 200-400mcg SC daily during active treatment - Helps manage Herxheimer reactions by dampening the inflammatory response to dying organisms - Some practitioners use KPV pre-treatment (1-2 weeks before starting antimicrobials) to reduce baseline inflammation **Nebulized Use for Respiratory Inflammation:** - KPV 100-200mcg in 2-3mL sterile saline, nebulized 1-2x daily - Used for: CIRS-related respiratory inflammation, chronic sinusitis, post-COVID airway inflammation - Anti-inflammatory effect on airway epithelium without direct antimicrobial action - Can be alternated with nebulized LL-37 (antimicrobial) and nebulized glutathione (antioxidant) **Topical / Dermatological:** - KPV compounded into topical cream/gel (concentration varies): for inflammatory skin conditions - Applied to affected areas 1-2x daily - Used in: eczema, psoriasis flares, post-procedure inflammation, wound healing **Important Clinical Notes:** - KPV does NOT cause skin darkening (unlike alpha-MSH or melanotan) — no melanocortin receptor activity - KPV does NOT suppress appetite (unlike alpha-MSH which acts on MC4R) - Very well-tolerated — minimal side effect profile in clinical use - Can be used alongside conventional anti-inflammatory medications (NSAIDs, steroids) without interaction - Store reconstituted peptide refrigerated; use within 30 days
Dosing Protocols
- Dose
- 200mcg
- Frequency
- Once daily
- Timing
- Morning on an empty stomach
- Route
- subcutaneous
- Cycle
- 4-12 weeks
Fasted dosing maximizes absorption; morning timing allows anti-inflammatory MSH-pathway activation during daytime digestive activity
- Dose
- 400mcg
- Frequency
- Once daily
- Timing
- Morning on an empty stomach, 30 minutes before food
- Route
- oral
- Cycle
- 4-12 weeks
Oral dosing delivers KPV directly to GI tract for local anti-inflammatory action; higher dose compensates for reduced oral bioavailability
Contraindications & Cautions
- hard stop — PregnancyNo human safety data exists for KPV (alpha-MSH fragment) during pregnancy. Anti-inflammatory and melanocortin pathway effects pose theoretical risk to fetal development.Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
- hard stop — BreastfeedingNo data on excretion in breast milk or effects on nursing infant. Safety has not been established.Action: Do not use while breastfeeding.
- hard stop — Under 18 years of agePeptide protocols are not designed for pediatric use. Insufficient safety data in minors.Action: Do not provide peptide protocols to individuals under 18.
Stacks featuring this peptide
BPC-157 (heals gut mucosa, reduces inflammation) + Larazotide (tightens gut junctions, reduces permeability) + KPV (anti-inflammatory tripeptide, NF-kB inhibition). Triple approach: heal tissue (BPC-157), seal the barrier (larazotide), and calm inflammation (KPV).
Targets the bidirectional gut-brain axis — gut inflammation drives anxiety/depression via vagal afferents and inflammatory cytokines crossing the blood-brain barrier, while stress/anxiety increases intestinal permeability and inflammation via the HPA axis. BPC-157 heals the gut mucosa and has documented gastroprotective effects (animal studies show complete reversal of NSAID-induced gut damage). KPV (alpha-MSH fragment) suppresses intestinal NF-κB, reducing the inflammatory signaling that reaches the brain. Selank (tuftsin analog) reduces anxiety and normalizes cortisol — breaking the stress → gut permeability → inflammation → more stress cycle from the brain side. Treating both ends of the axis simultaneously produces faster resolution than targeting either alone.
BPC-157 was originally derived from human gastric juice and has a strong affinity for GI tissue. It promotes angiogenesis, modulates the nitric oxide system, and accelerates mucosal healing. KPV is an alpha-MSH fragment with potent anti-inflammatory effects that specifically target intestinal epithelial cells by inhibiting NF-kB activation. BPC-157 rebuilds the gut lining while KPV calms the inflammatory cascade — addressing both the structural damage and the underlying inflammation in gut disorders.
For autoimmune conditions with a gut permeability component (Crohn's, ulcerative colitis, celiac, rheumatoid arthritis with gut involvement). KPV (alpha-MSH tripeptide) is a potent NF-κB inhibitor that directly suppresses the inflammatory cascade driving autoimmune flares. BPC-157 heals the gut mucosa and modulates the nitric oxide system, addressing the tissue damage from chronic inflammation. Thymosin Alpha-1 rebalances T-cell subsets — shifting from Th17/pro-inflammatory toward Treg/regulatory phenotype. Larazotide seals tight junctions, reducing the gut permeability that allows antigenic proteins to trigger systemic immune responses. The "leaky gut → immune activation → tissue damage" cycle is addressed at every node.
Research Summary
**Tier 1 — Established Pharmacology:** - Alpha-MSH anti-inflammatory pathway is extensively characterized (hundreds of publications) - KPV identified as the minimal active anti-inflammatory sequence of alpha-MSH (Brzoska et al., 2008; Getting et al., multiple publications) - NF-kB inhibition by KPV: well-documented in multiple cell types and inflammatory models - PepT1 transporter-mediated uptake of KPV in intestinal epithelium: demonstrated by Dalmasso et al. (J Biol Chem, 2008) **Tier 2 — Translational/Animal Studies:** - Experimental colitis (DSS and TNBS models): oral and SC KPV significantly reduces disease severity scores, histological inflammation, and cytokine levels (Dalmasso et al., PLoS One 2008; Kannengiesser et al., 2008) - Nanoparticle-encapsulated KPV for targeted colonic delivery: enhanced efficacy in colitis models (Laroui et al., 2010) - KPV in experimental arthritis: reduces joint inflammation and cartilage destruction in animal models - Skin inflammation: KPV reduces contact hypersensitivity and UV-induced inflammation in mouse models **Tier 3 — Emerging/Clinical Translation:** - No completed human RCTs specifically for KPV (as distinct from alpha-MSH) - Practitioner-level evidence: extensive use in functional medicine for gut inflammation, CIRS, and Lyme disease — case series and clinical observation rather than controlled trials - Oral bioavailability: KPV as a tripeptide is absorbed via PepT1 (demonstrated), but systemic bioavailability after oral dosing is not fully characterized in humans - KPV-loaded hydrogels and nanoparticles for targeted GI delivery: active research area - Investigation in IBD: KPV is a candidate for clinical trials in ulcerative colitis and Crohn's disease based on strong preclinical rationale